FDA panel unanimously approves Merck HIV drug

An FDA panel of outside experts has come to a unanimous decision in support of accelerated approval of Merck's experimental HIV drug Isentress, for patients who have stopped responding to other treatments. Although the FDA is not expected to rule on the drug until mid-October, the panel's recommendation implies a greater chance for Isentress to obtain federal approval.

View Full Article in:

CNNMoney · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ